Cost effectiveness modelling
Cost-effectiveness models inform economic decisions by computing a ratio of benefit, value or output to cost incurred to achieve such output. Cost-effectiveness analysis in healthcare usually implies selecting Quality Adjusted Life year or QALY as a generic measure of health benefit, although other health outcomes such as Life Years (LY), Hospitalisations averted or Lengths of Stay (LoS) can be selected.
Cost-effectiveness modelling involves calculating an incremental cost-effectiveness ratio that compares added benefit to added cost. This ratio is then compared to a threshold value that differs in various countries. The threshold value often reflects the opportunity cost of generating one QALY in a given healthcare system. 
Organizations such as the National Institute for Health and Care Excellence in Britain, Zorginstituut in the Nederlands, the nonprofit Institute for Clinical and Economic Review in the United States, PHARMAC in New Zealand, and other international agencies review modeling cost-effectiveness in healthcare. They demonstrated that cost-effectiveness analysis can help inform appropriate pricing. [2,3,4,5]
Cost effectiveness modelling requires rigorous selection of health states to be included in the model structure. Usually this involves simulating the number of hypothetical patients in specific states (no, acute, chronic disease state) and generic states (alive or absorbing state) of interest over time. Specialized microsimulation software packages exist to perform such analysis.
Cost Effectiveness model types:
Markov cohort model
Involves following a cohort of patients or a single patient over a lifetime and capturing disease related outcomes of interest. The cohort can be followed with shorter time horizons, if they are long enough to capture all costs and benefits followed by introducing a healthcare intervention. At the end of the digital simulation all patients in the cohort must end up in an “absorbing” state.
Steady state model (population-based)
In contrast to cohort modeling, population based approach doesn’t imply application of all-cause-mortality rates, but calculates the number of patients in each age group based on the current cross-sectional snapshot of the current demographic profile. 
Uncertainty analysis is an essential part of model results robustness check.
One-way sensitivity analysis (OWSA) - evaluates an impact of each individual input parameter on outcomes of interest. The result is display in form of “Tornado” diagram presenting most impactful parameters at the top and least impactful at the bottom.
Multi-way sensitivity analysis – evaluates the impact of two or more parameters at the same time. For example this can be varying the efficacy of treatment strategy and the discount rate used to calculate the present value of future outcomes.
Scenario analysis – evaluates the impact of a specific combination of input parameters (cost, effect, patient sub-group) to reflect one or several scenarios and estimates of incremental cost-effectiveness ratio (ICER).
Probabilistic sensitivity analysis (PSA) – evaluates the impact of a change in all input parameters at the same time. Each input parameter is assigned a statistical distribution (normal, log-normal, beta, gamma, triangular). A Monte-Carlo simulation is a mathematical technique used to run PSA. It involves sampling from a distribution around the mean input value to create a set of probabilistic inputs and therefore a probabilistic result. PSA run usually involves 1,000 or more iterations and plotting the cost and QALY difference results on a cost-effectiveness plane, creating a “cloud of uncertainty” around deterministic estimate of Cost per QALY.
Involves evaluating the impact of changes in model structure. For example addition or deletion of health states, change of modeling methodology (static vs. dynamic, population vs. cohort-based).
Get in touch!
Fill up the form and our Team will get back to you within 24 hours.